IL15 and neoplasm: Transgenic tumor-bearing mice were split into 10 cohorts and treated with either CD147-CAR-NK or CD147-IL15-CAR-NK therapy, and tissues were harvested on days 0, 1, 5, 7, and 14 (Figure 3A).